Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome

Dermatologic Therapy

Volumn 19, Issue 4, 2006, Pages 210-223

  Lowenstein, Eve J ^a,b  

^a Box #46 ^*  (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Acne; Hyperandrogenism; Polycystic ovary

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIANDROGEN; BIGUANIDE; BROMOCRIPTINE; CIMETIDINE; CONTRACEPTIVE AGENT; CYCLOSPORIN; CYPROTERONE ACETATE; DESOGESTREL; DIAZOXIDE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; GLUCOPHAGE XL; KETOCONAZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; METFORMIN; MINOXIDIL; NORGESTIMATE; ORNITHINE DECARBOXYLASE INHIBITOR; ORTHOCEPT; ORTHOCYCLIN; PHENYTOIN; PIOGLITAZONE; ROSIGLITAZONE; SABAL EXTRACT; SPIRONOLACTONE; STEROID; VALPROIC ACID;

ACANTHOSIS NIGRICANS; ACNE; ACROMEGALY; ADRENAL HYPERPLASIA; ALOPECIA; ANDROBLASTOMA; BONE DENSITY; CLINICAL FEATURE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG SAFETY; HEART FAILURE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPOGONADISM; HYPOTHYROIDISM; LIBIDO DISORDER; LIVER TOXICITY; OBESITY; OVARY POLYCYSTIC DISEASE; PROLACTINOMA; REVIEW; RISK FACTOR; SABAL; SIDE EFFECT; SKIN DISEASE; TERATOMA; WEIGHT GAIN;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; PREVALENCE; SKIN DISEASES;

EID: 33748640794     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2006.00077.x     Document Type: Review

References (144)

1. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005: 83 : 1717-1723.
2. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004: 18: 671-683.
3. Fauser B. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary disease (PCOS). Hum Reprod 2003: 19: 41-47.
4. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endrocrinol 2001: 55: 667-672.
5. Franks S. Polycystic ovary syndrome. N Engl J Med 1995: 333: 853-861.
6. Goldzieher JW, Grenn JA. The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 1962: 22: 325-338.
7. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003: 9: 505-514.
8. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and ideopathic hirsutism. Br Med J 1986: 293: 355-359.
9. Moran L, Norman RJ. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004: 18: 719-736.
10. Fraser IS, Kovacs G. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004: 18: 813-823.
11. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001: 86:.
12. Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006: 91: 36-42.
13. Agrawal R, Sharma S, Bekir J, et al. Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women. Fertil Steril 2004: 82: 1352-1357.
14. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003: 362: 1082.
15. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod 2002: 17: 2219-2227.
16. Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol 1998: 1: 91-99.
17. Ehrmann D. Polycystic ovary syndrome. N Engl J Med 2005: 352: 1223-1236.
18. Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004: 18: 707-718.
19. Carey AH, Chan KI, Short F, White DM, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol 1993: 38: 653-658.
20. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992: 327: 157-162.
21. Nelson VL, Qin Kn KN, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001: 86: 5925-5933.
22. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary disease: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol 2002: 16: 275-284.
23. Schmidt JB, Spona J, Huber J. Androgen receptor in hirsutism and acne. Gynecol Obstet Invest 1986: 22: 206-211.
24. Lobo R. Hirsutism in polycystic ovary syndrome: current concepts. Clin Obstet Gynecol 1991: 34: 817-826.
25. Goldzieher JW, Axelrod LR. Clinical and biochemical features of polycystic ovarian disease. Fertil Steril 1963: 14: 631-653.
26. Aono T, Miyazaki M, Miyake A, Kinugasa T, Kurachi K, Matsumoto K. Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries. Acta Endocrinol 1977: 85: 840-849.
27. Ruutiainen K, Erkkola R, Gronroos MA, Irjala K. Influence of body mass index and age on the grade of hair growth in hirsute women of reproductive ages. Fertil Steril 1988: 50: 260-265.
28. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992: 167: 1807-1812.
29. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR. Idiopathichirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril 1998: 70: 274-278.
30. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004: 18: 737-754.
31. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003: 101: 995-1007.
32. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin and anti-androgen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003: 88: 4116-4123.
33. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002: 147: 217-221.
34. Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol 1989: 121: 675-680.
35. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999: 41: 577-580.
36. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol 1997: 24: 223-229.
37. Eden J. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Aust 1991: 155: 677-680.
38. Betti R, Bencini PL, Lodi A, Urbani CE, Chiarelli G, Crosti C. Incidence of polycystic ovaries in patients with late-onset or persistent acne: hormonal reports. Dermatologica 1990: 181: 109-111.
39. Toscano V, Balducci R, Bianchi P, et al. Two different pathogenetic mechanisms may play a role in acne and in hirsutism. Clin Endocrinol 1993: 39: 551-556.
40. Serafini P, Ablan F, Lobo RA. 5-Alpha reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985: 60: 349-355.
41. Horton R. Dihydrotestosterone is a peripheral paracrine hormone. J Androl 1992: 13: 23-27.
42. Greep N, Hoopes M, Horton R. Androstanediol glucuronide plasma clearance and production rates in normal and hirsute women. J Clin Endocrinol Metab 1986: 62: 22-27.
43. Falsetti L, Rosina B, De Fusco D. Serum levels of 3alpha-androstanediol glucuronide in hirsute and non-hirsute women. Eur J Endocrinol 1998: 138: 421-424.
44. Borgia F, Cannavo S, Guarner F, Cannavo SP, Vaccaro M, Guarner B. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol 2004: 84: 201-204.
45. Henze C, Hinney B, Wuttke W. Incidence of increased androgen levels in patients suffering from acne. Dermatology 1998: 196: 53-54.
46. Slayden SM, Moran C, Sams WM Jr, Boots LR, Azziz R. Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001: 75: 889-892.
47. Brown S, Shalita A. Acne vulgaris. Lancet 1998: 351: 1871-1876.
48. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993: 76: 524-528.
49. Cela E, Robertson C, Rush K, et al. Prevalence of polycystic ovaries in women with androgenetic alopecia. Eur J Endocrinol 2003: 149: 439-442.
50. Tafeit E, Moller R, Rackl S, et al. Subcutaneous adipose tissue pattern in lean and obese women with polycystic ovary syndrome. Exp Biol Med (Maywood) 2003: 228: 710-716.
51. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol 1994: 41: 473-481.
52. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995: 10: 2107-2111.
53. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988: 50: 197-212.
54. Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 1991: 73: 590-595.
55. Sampaolo P, Livieri C, Montanari L, Paganelli A, Salesi A, Lorini R. Precocious signs of polycystic ovaries in obese girls. Ultrasound Obstet Gynecol 1994: 4: 310-315.
56. Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol 1987: 67: 175-177.
57. Elmer KB, George RM. HAIR-AN syndrome: a multisystem challenge. Am Fam Physician 2001: 63: 2385-2390.
58. Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. Horm Res 2000: 54: 251-258.
59. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983: 147: 90-101.
60. Amesse LS, Ding X, Pfaff-Amesse T. From HAIR-AN to eternity. J Pediatr Adolesc Gynecol 2002: 15: 235-240.
61. Kim SS, Rosenfield RL. Hyperhidrosis as the only manifestation of hyperandrogenism in an adolescent girl. Arch Dermatol 2000: 136: 430-431.
62. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of non-classical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985: 37: 650-667.
63. Bakerman S, Bakerman P, Strausbach P. ABC's of interpretive laboratory data, 3rd ed. Myrtle Beach, SC: Interpretive Laboratory Data, 1994.
64. Hague WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol 1990: 33: 501-510.
65. O'Driscoll JB, Mamtora H, Higginson J, Pollock A, Kane J, Anderson DC. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenetic alopecia. Clin Endocrinol 1994: 41: 231-236.
66. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 2004: 18: 685-706.
67. Walton S, Cunliffe WJ, Keczkes K, et al. Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Br J Dermatol 1995: 133: 249-253.
68. Cibula D, Hill M, Vohrandnikova O, Kuzel D, Fanta M, Zivny J. The role of androgens in determining acne severity in adult women. Br J Dermatol 2000: 143: 399-404.
69. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol 2005: 62: 644-649.
70. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000: 85: 139-146.
71. Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary disease. Fertil Steril 1984: 41: 719-725.
72. Murdoch AP, Dunlop W, Kendall-Taylor P. Studies of prolactin secretion in polycystic ovary disease. Clin Endocrinol 1986: 24: 165-175.
73. Panidis D, Balaris C, Farmakiotis D, et al. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 2005: 51: 1691-1697.
74. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003: 206: 57-67.
75. Breitkopf D, Rosen M, Young S, Nagamani M. Efficacy of second- versus third-generation oral contraceptives in the treatment of hirsutism. Contraception 2003: 67: 349-353.
76. Redmond G, Olson W, Lippman J, Kafrissen M, Jones T, Jorizzo J. Morgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997: 89: 615-622.
77. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer JL. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997: 37: 746-754.
78. Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestrone and desogestrel in young women with acne vulgaris. Contraception 1996: 53: 163-170.
79. van Vloten W, van Haselen C, van Zuuren E, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospiranone or cyproterone acetate on acne and seborrhea. Cutis 2002: 69: 2-15.
80. Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 2004: 30: 163-165.
81. Falsetti L, Gambera A, Platto C, Legrenzi L. Management of hirsutism. Am J Clin Dermatol 2000: 1: 89-99.
82. Barth JH, Cherry CA, Wojnarowska F, Dauber RP. Cyproterone acetate for severe hirsutism: results of a double-blind dose ranging study. Clin Endocrinol 1991: 35: 5-10.
83. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Human Reprod 1998: 13: 2706-2711.
84. Zemtsov A, Wilson L. Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy. Arch Dermatol 1997: 133: 431-433.
85. Dorrington-Ward P, McCartney AC, Holland S, et al. The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol 1985: 23: 161-167.
86. Erenus M, Yucelten D, Durmusoglu F, Gurbuz O. Comparison of finasteride versus spironolactone in treatment of ideopathic hirsutism. Fertil Steril 1997: 68: 1000-1003.
87. Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994: 61: 281-287.
88. Helfer EL, Miller JL, Rose LI. Side effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metab 1988: 66: 208-211.
89. Sawaya M. Antiandrogens and androgen inhibitors. In: Se W, ed. Comprehensive dermatologic drug therapy. Philadelphia: W.B. Saunders Co., 2001: 385-401.
90. Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA 1982: 247: 1295-1298.
91. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide and finasteride efficacy in treatment of hirsutism: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000: 85: 89-94.
92. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective, randomized trial comparing low-dose flutamide, finasteride, ketoconazole and cyproterone acetate-estrogen regiments in the treatment of hirsutism. J Clin Endocrinol Metab 1999: 84: 1304-1310.
93. Yulceten D, Erenus MGO, Durmusoglu F. Recurrence rate of hirsutism after three different antiandrogen therapies. J Am Acad Dermatol 1999: 41: 64-68.
94. Muderris II, Bayram F, Sahin Y, Kelestimur F. A comparison between two doses of flutamide on the treatment of hirsutism. Fertil Steril 1997: 68:.
95. Falsetti L, Gambera A, Legrenzi L, Lacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999: 141: 361-367.
96. Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Curr Pharm Des 1999: 5: 707-723.
97. Muderris II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000: 73: 984-987.
98. Marcondes JA, Minnani SL, Luthold WW, Wajchenberg BL, Samojlik E, Kirschner MA. Treatment of hirsutism in women with flutamide. Fertil Steril 1992: 57: 543-547.
99. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 2004: 60: 241-249.
100. Muderris II, Bayram F, Guven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 2000: 14: 38-41.
101. Hatwal A, Bhatt RP, Agrawal JK, Singh G, Bajpai HS. Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol 1988: 68: 84-87.
102. Golditch IM, Price VH. Treatment of hirsutism with cimetidine. Obstet Gynecol 1990: 75: 911-913.
103. Lissak A, Sorokin Y, Calderon I, Dirnfeld M, Lioz H, Abramovici H. Treatment of hirsutism with cimetidine: a prospective randomized controlled trial. Fertil Steril 1989: 51: 247-250.
104. Aram H. Treatment of female androgenetic alopecia with cimetidine. Int J Dermatol 1987: 26: 128-130.
105. Gokmen O, Senoz S, Gulekli B, et al. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol 1996: 10: 249-255.
106. Sonino N, Scaroni C, Biason A, Boscaro M, Mantero F. Low-dose ketoconazole treatment in hirsute women. J Endocrinol Invest 1990: 13: 35-40.
107. Venturoli S, Fabbri R, Dal Prato L, et al. Ketoconazole therapy for women with acne and/or hirsutism. J Clin Endocrinol Metab 1990: 71: 335-339.
108. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastoenterology 1984: 86: 503-513.
109. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alfareductase in the treatment of androgenetic alopecia. J Altern Complement Med 2002: 8: 143-152.
110. Azziz R, Ochoa TM, Bradley EL, Potter HD, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab 1995: 80: 3406-3411.
111. Morcos RN, Abdul-Malak ME, Shikora E. Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy. Fertil Steril 1994: 61: 427-431.
112. Petrone A, Civitillo RM, Galante L, et al. Usefulness of a 12-month treatment with finasteride in idiopathic and polycystic ovary syndrome-associated hirsutism. Clin Exp Obstet Gynecol 1999: 26: 312-216.
113. Tolino A, Petrone A, Sarnacchiaro F, et al. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 1996: 66: 61-65.
114. Bayram F, Muderris II, Sahin Y, Kelestimur F. Finasteride treatment for one year in 35 hirsute patients. Exp Clin Endocrinol Diabetes 1999: 107: 195-197.
115. Bayram F, Muderris II, Guven M, Kelestimur F. Comparison of high-dose finasteride (5 mg/day) versus low-dose (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol 2002: 147: 467-471.
116. Balfour JA, McClellan K. Topical eflornithine. Am J Clin Dermatol 2001: 2: 197-201.
117. Trueb R. Causes and management of hypertrichosis. Am J Clin Dermatol 2002: 3: 617-627.
118. Sahin Y, Kelestimur F. Medical treatment regimens of hirsutism. Reprod Biomed Online 2004: 8: 538-546.
119. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999: 84: 1470-1474.
120. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004: 82: 421-429.
121. Pasquali R, Fabbri R, Venturoli S, Paradisi R, Antenucci D, Melchionda N. Effect of weight loss and anti-androgenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries. Am J Obstet Gynecol 1986: 154: 139-144.
122. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992: 36: 105-111.
123. Manco M, Castagneto M, Nanni G, et al. Biliopancreatic diversion as a novel approach to the HAIR-AN syndrome. Obes Surg 2005: 15: 286-289.
124. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003: 361: 1894-1901.
125. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2005: 30: epub.
126. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995: 80: 2057-2062.
127. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainem HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998: 69: 691-696.
128. Kolodziejczyk B, Duleba A, Spaczynski R, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000: 73: 1149-1154.
129. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000: 85: 2767-2774.
130. Homburg R. Should patients with polycystic ovary syndrome be treated with metformin? A note of cautious optimism. Hum Reprod 2002: 17: 853-856.
131. Fleming R, Hopkinson ZE, Wallace M, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomised, double-blinded, placebo-controlled trial. J Clin Endocrinol Metab 2002: 87: 1-6.
132. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Response of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005: 90: 1360-1365.
133. Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998: 196: 148-152.
134. Boudou P, Soliman H, Chivot M, et al. Effect of oral isotretinoin treatment on skin androgen receptor levels in male acneic patients. J Clin Endocrinol Metab 1995: 80: 1158-1161.
135. Gomez EC, Moskowitz RJ. Effect of 13-cis-retinoic acid on the hamster flank organ. J Invest Dermatol 1980: 74: 392-397.
136. Lowenstein E. Isotretinoin made S.M.A.R.T. and simple. Cutis 2002: 70: 115-120.
137. Murdoch AP, McClean KG, Watson MJ, Dunlop W, Kendall-Taylor P. Treatment of hirsutism in polycystic ovary syndrome with bromocriptine. Br J Obstet Gynaecol 1987: 94: 358-365.
138. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulinlike growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992: 98: 82S-85S.
139. Omar HA, Logsdon S, Richards J. Clinical profiles, occurrence, and management of adolescent patients with HAIR-AN syndrome. Scientific World J 2004: 8: 507-511.
140. Walling HW, Messingham M, Myers LM, Mason CL, Strauss JS. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol 2003: 2: 677-681.
141. Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated insulin resistance: pathophysiology and management. Am J Clin Dermatol 2004: 5: 199-203.
142. Rosenbach A, Ram R. Treatment of acanthosis nigricans of the axillae using long-pulsed (5-msec) alexandrite laser. Dermatol Surg 2004: 30: 1158-1160.
143. Pfeifer SL, Wilson RM, Gawkrodger DJ. Clearance of acanthosis nigricans associated with the HAIR-AN syndrome after partial pancreatectomy: an 11-year follow-up. Postgrad Med J 1999: 75: 421-423.
144. Cordain L, Eades MR, Eades MD. Hyperinsulinemic diseases of civilization: more than just. Syndrome X Comp Biochem Physiol Am Mol Integr Physiol 2003: 136: 95-112.